International Cancer Genome Consortium authorizes 1,000th user

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE INTERNATIONAL CANCER GENOME CONSORTIUM authorized its 1,000th user, giving them access to the Consortium’s Controlled Access datasets. ICGC datasets that catalogue tumor-specific mutations are unrestricted and freely available to the scientific community. However, the consortium developed an authorization process to distribute clinical and inherited genetic data associated with unique individuals in order to minimize...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

“Our goal was very clear from the beginning, which was to develop a user-friendly simple chat-like interface that would provide specific high-quality answers to questions that our members would bring, utilizing only our content,” said Clifford A. Hudis, CEO of the American Society of Clinical Oncology and executive vice chair of the Conquer Cancer Foundation.
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login